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Background  and  purpose:  Lipoprotein  (Lp)  (a)  is  a  neglected  element  of  the  blood  lipid proﬁle.  It  is  now
recognized  as  a  determinant  of coronary  heart  disease  progression  and  its  role  in atherosclerosis  and
its ability  to  induce  thrombosis  make  it potentially  important  in  the  course  of  normal  and  complicated
pregnancies.  Pregnancy  involves  a major  transformation  of  metabolism  to  sustain  fetal  growth.  Multiple
studies  have  been  conducted  on Lp(a)  in  pregnancy,  and  it is timely  to  synthesize  and  evaluate  this
evidence.
Methods  and  subjects:  We  reviewed  the MEDLINE  database  for all articles  published  concerning  “lipopro-
tein  a”  and  “pregnancy”  from  May  2003  to  May  2012.  A  previous  comprehensive  review  assessed  the
literature  up  to  May  2003.
Results:  We  critically  analyzed  14  studies  detailing  the  effect  of complications  in pregnancy  on Lp(a)
proﬁle,  and  subsequent  pregnancy  outcomes  where  available.  Studies  evaluating  the  normal  metabolic
response  to  pregnancy,  pregnancies  complicated  by pre-eclampsia  and  intra-uterine  growth  restriction
were reviewed.
Conclusions:  A  substantial  mass  of  data  has  accumulated  describing  Lp(a)  changes  in pregnancy.  The
diversity  of study  design  limits  the  ability  to  draw  broad-ranging  conclusions,  but brings  into  focus  the
important  questions  remaining,  which  we  discuss.© 2012  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
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Lipoprotein (Lp) (a) is a subclass of lipoprotein, consisting of a
ow-density lipoprotein (LDL) covalently bound via its apolipopro-
ein B100 portion to apolipoprotein (apo) (a) [1].  It was  discovered
y Berg in 1963 and increased levels of Lp(a) have been correlated
ith increased risk of coronary heart disease (CHD), although the
ature of this relationship is not clear [2,3]. Lp(a) forms an impor-
ant part of the clinical biomarker proﬁle of patients with CHD and
eart failure [4,5]. In addition to the role of Lp(a) in atherosclerosis,
he apo(a) element of Lp(a) has a structure similar to plasmino-
en, allowing Lp(a) particles to reduce the physiological ﬁbrinolytic
ctivity of plasminogen by competitively binding endothelial plas-
inogen receptors [6].  It is this pro-thrombotic effect, together
ith Lp(a) accumulation in atherosclerotic lesions, that is thought
o predispose those with high levels to CHD [7].
The plasma concentration of Lp(a) is mainly governed by the
ene locus for apo(a), located on chromosome 6. Although high
evels of Lp(a) are inherited in a dominant fashion, other genes
nd other factors (diet, hormones and disease states) can inﬂuence
p(a) concentrations [8,9]. Polymorphisms in the apo(a) gene pro-
uce isoforms of apo(a) of different sizes. The smaller the isoform,
he higher the Lp(a) concentration – a phenomenon which accounts
or 40% of the variation of Lp(a) concentration [10,11]. The relation-
hip between apo(a) isoform size and CHD and vascular disease is
omplex. A large systematic review from 2010 showed a twofold
igher risk of CHD and ischemic stroke in subjects with smaller
po(a) isoforms [12]. Other studies have suggested smaller apo(a)
soforms predict angina symptoms better than Lp(a) concentrations
13]. However, more recent studies have found that the apo(a) iso-
orm size contributes little to the relationship between Lp(a) and
HD and is not an independent risk factor for CHD [14]. Therefore,
here is evidence that both Lp(a) isoform size and concentration and
he interaction of these variables with patient-speciﬁc factors are
mportant in determining CHD and stroke risk. The precise nature
f this interaction needs further elucidation.
The production of Lp(a) occurs at the hepatocyte surface and
learance is via the kidney [15]. The standard reference plasma con-
entration of Lp(a) is <0.1 to >300 mg/dL in Caucasians, with mean
oncentrations of 15 mg/dL [16]. Although plasma levels of Lp(a)
re similar in both men  and women, gender inﬂuences the cardio-
ascular risk. At similarly high levels of plasma Lp(a), women are
ore likely to experience CHD than men  [2,17].
hat is known about Lp(a) in pregnancy?
Lp(a) has been studied in both normal pregnancies and preg-
ancies complicated by various disease states, e.g. pre-eclampsia.
n healthy pregnant women, lipid metabolism is altered over the
ourse of pregnancy to result in a hyperlipidemic third-trimester
tate [18–20].  This is due to a combination of the direct effect of
strogen on lipid synthesis in the liver, as well as a state of rel-
tive insulin resistance (thereby releasing free fatty acids from
dipocytes). Triglyceride levels increase markedly, with cholesterol
nd phospholipid levels increasing more modestly [21]. Hyperlipi-
emia in pregnancy provides a functional reservoir for the fetus
 allowing cholesterol, for example, to be used for building fetal
ellular membranes, steroid hormones, and bile acids [22,23]. Pre-
clampsia is a disorder of uncertain pathogenesis, characterized
y hypertension and proteinuria from the 20th week of preg-
ancy onwards. Endothelial cell injury, resulting in coagulation
nd vasoconstriction, is thought to play a role in its pathogenesis
24]. The similarity between this and the process of atherosclero-
is – together with the antiﬁbrinolytic properties of Lp(a) – has led
esearchers to consider the role of Lp(a) in pre-eclampsia. A pro-
hombotic state has also been postulated to be important in thef Cardiology 61 (2013) 99–106
pathogenesis of other diseases of pregnancy including intrauterine
growth restriction (IUGR) (deﬁned as a fetus that is pathologically
small, often a product of pre-eclampsia) and recurrent pregnancy
loss (RPL) (deﬁned as 3 or more consecutive pregnancies miscarried
at <20 weeks gestation) [25].
A number of unanswered questions remain. What is the role
of Lp(a) in both normal and complicated pregnancies? Does Lp(a)
have a role in pregnancies complicated by conditions other than
pre-eclampsia and IUGR? If Lp(a) is increased in normal pregnancy,
what is the physiological signiﬁcance of this? If not, what are its
exact effects? What is the mechanism of the increased Lp(a) con-
centration – is it attributable more to genetics or to environment
(e.g. change in diet)? What impact does a raised Lp(a) in pregnancy
have on the developing fetus (and its future cardiovascular risk)?
How does having a twin pregnancy impact upon levels of Lp(a)?
Answers to these questions will determine how Lp(a) levels should
be managed in pregnancy.
Methods
Search criteria
The literature pertaining to Lp(a) in pregnancy was compre-
hensively reviewed from January 1966 up to May  2003 by Manten
et al. in 2005 [26]. The authors concluded that studies up to 2003
yielded diverse results, with no consensus on the role of Lp(a) in any
condition studied (normal pregnancy, pregnancies complicated by
pre-eclampsia or IUGR) – in part due to differing methodologies.
This will be addressed further in “Discussion” section.
In this review, a MEDLINE search was  performed to identify
relevant articles published between May  2003 and May  2012,
written in the English language. Search items were: “Lipopro-
tein a in pregnancy”, “Lipoprotein a in normal pregnancy”,
“Lipoprotein a in complicated pregnancy”, “Lipoprotein a in pre-
eclampsia/preeclampsia” and “Lipoprotein a in IUGR”. All relevant
articles were included in the analysis. Other relevant papers were
identiﬁed through the reference sections of articles. Articles were
excluded if they pertained to neonatal sequelae of high Lp(a).
Results
Study characteristics
A  total of 14 relevant articles were identiﬁed (Tables 1 and 2).
Eight of these were case–control studies, one was interventional,
one was  longitudinal, three were cross-sectional and, one was  both
case–control and longitudinal. The number of subjects ranged from
19 to 544. Most studies had subjects either of only Caucasian or
unknown ethnicity. Most authors used a method of measuring Lp(a)
that was  not apo(a) isoform-independent, which – given that Lp(a)
concentration is inﬂuenced by apo(a) isoform size – can lead to
over- or under-estimations of Lp(a) concentration. Most did not
analyze the nature of the apo(a) isoforms. Most of the studies used
women in their 3rd trimester of pregnancy as subjects.
Nine of the studies focused on comparing Lp(a) levels in healthy
pregnant women  to Lp(a) levels in women  with pre-eclampsia in
the 3rd trimester of pregnancy (Table 1) [27–35].  One of these
nine studies also looked at Lp(a) levels in the fetus [30] and one
of these studies additionally compared Lp(a) levels in women  with
a history of IUGR [31]. Two of the studies examined Lp(a) levels
in healthy pregnant women  [36,37], one of which compared levels
in healthy non-pregnant women [36]. One study examined Lp(a)
levels in pregnant women  with familial hypercholesterolemia (FH)
compared to healthy pregnant controls [38]. And two of the stud-
ies examined Lp(a) levels in women with a history of RPL [39,40].
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Table 1
Studies investigating the role of Lp(a) in pregnancies affected by pre-eclampsia.
Study Design No. pts Population characteristics Age of women (years) Ethnicity Apo(a)
isoform
typing
Method of Lp(a)
measurement
Results Pregnancy
outcomes
Bukan et al. [28] CC 41 16 women with normal
pregnancies, 25 women with
pre-eclampsia (2nd/3rd
trimesters)
Subjects 33.64 ± 6.05,
controls 35.2 ± 4.8
U No Nephelometry No difference in Lp(a) levels
between subjects with
pre-eclampsia vs healthy
controls
N/A
Demir  et al. [27] CC 70 35 women with normal
pregnancies, 35 women with
pre-eclampsia (all 3rd
trimester)
Subjects 28.8 ± 6.6,
controls 29.4 ± 4.1
U No Nephelometry Increased levels of Lp(a) in
subjects with pre-eclampsia vs
healthy controls (p < 0.0001)
Not assessed
Parvin  et al. [29] CC 60 30 women  with normal
pregnancies, 30 women  with
pre-eclampsia (all 3rd
trimester)
Subjects 23.73 ± 4.33,
controls 23.40 ± 3.04
U No Nephelometry Increased levels of Lp(a) in
subjects with pre-eclampsia vs
healthy controls (p < 0.001)
Not assessed
Catarino et al. [30] CC 88 42 women with normal
pregnancies, 46 women with
pre-eclampsia (all 3rd
trimester) (maternal blood
samples and fetal umbilical
cord blood samples)
Subjects 29.7 ± 5.3,
controls 30.4 ± 5.7 [GA
of subjects = 37.0
(34–38), GA of
control = 38.5
(38–39.3)]
U No Immunoturbidimetry No difference in Lp(a) levels
between subjects with
pre-eclampsia vs healthy
controls (both maternal and
fetal samples)
N/A
Manten  et al. [31] CC 368 53 women with a history of
normal pregnancy, 256 women
with a history of
pre-eclampsia, 59 women  with
a history of IUGR (all studied at
least 3 months PP)
Subjects with a history
of pre-eclampsia 31 ± 4
(statistically signiﬁcant
difference from
controls), subjects with
a history of IUGR
32 ± 4, controls 33 ± 4
C No Apo(a)
isoform-independent
ELISA
No difference in Lp(a) levels
between subjects with
pre-eclampsia vs IUGR vs
healthy controls
N/A
Wang  et al. [33] I 26 13 women with normal
pregnancies, 13 women with
pre-eclampsia (outcome of
study to assess effect of
heparin-mediated apheresis)
(women with pre-eclampsia in
both 2nd/3rd trimesters,
women  with normal
pregnancies in 3rd trimester)
Subjects 33.0
(23.9–39.8), controls
33.9 (24.8–38.4)
C No Immunoturbidimetry No difference in Lp(a) levels
between subjects with
pre-eclampsia vs healthy
controls
Heparin-mediated apheresis
resulted in a reduction in Lp(a)
levels (by 49%) (p < 0.001)
Of  the 9 neonates
born to mothers
with pre-eclampsia
treated with
heparin-mediated
apheresis, 8 had
good clinical
outcomes. 1 died of
late-onset sepsis
Bayhan  et al. [34] CS 73 20 women  with normal
pregnancies, 25 women with
mild pre-eclampsia, 28 women
with severe pre-eclampsia (all
in 3rd trimester)
– – – Nephelometry Increased levels of Lp(a) in
subjects with mild and severe
pre-eclampsia vs healthy
controls
Positive correlation between
levels of Lp(a) and BMI  in
severely pre-eclamptic women
(p = 0.008)
–
Baksu  et al. [35] CS 131 40 healthy women  with
normal pregnancies, 48
women  with mild
pre-eclampsia, 43 women  with
severe pre-eclampsia (all in
3rd trimester)
Subjects with severe
pre-eclampsia 26.7
(17.0–38.0), subjects
with mild
pre-eclampsia 28.3
(19.0–43.0), controls
26.7 (19.0–37.0)
U No Turbidimetry No difference in levels of Lp(a)
between subjects with
pre-eclampsia vs healthy
controls
N/A
102 A.E. Fanshawe, M. Ibrahim / Journal o
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The results from these studies are shown in Table 1 (studies per-
taining to pre-eclampsia) and Table 2 (studies pertaining to normal
pregnancy or other pregnancy conditions).
What is the role of Lp(a) in normal pregnancy?
Two studies focused exclusively on normal pregnancies. Both
showed increased levels of Lp(a) compared to non-pregnant con-
trols. The case–control study of Lippi et al. showed increased levels
of Lp(a) in women in their 2nd/3rd trimester compared to women
in their 1st trimester/non-pregnant women [36]. The longitudinal
study of Manten et al. showed that levels of Lp(a) increased up to
the 35th week of gestation, then declined slightly before delivery,
before falling below 1st trimester levels by 3–5 months post-
delivery [37]. The longitudinal study design allowed the authors
to develop a formula for calculating reference Lp(a) levels accord-
ing to gestational age (GA). Two  mechanisms were proposed by the
authors to account for the rise in Lp(a). First, that the physiological
hyperlipidemia of pregnancy induces endothelial cell dysfunction
and that Lp(a) – acting in its role as an acute-phase protein – binds
to endothelial cells and promotes delivery of cholesterol to aid cel-
lular regeneration. Second, that increased levels of Lp(a) may act to
fulﬁll the demand for increased steroid hormone synthesis in preg-
nancy. The decrease in Lp(a) toward delivery may be accounted for
by increased consumption secondary to increased endothelial cell
damage.
What is the role of Lp(a) in pregnancy complicated by
pre-eclampsia?
Nine studies evaluated Lp(a) in pre-eclampsia [one of which
additionally compared Lp(a) levels in women with a history of
IUGR]. Three showed an increased level of Lp(a) in subjects with
pre-eclampsia compared to healthy pregnant controls [27,29,34].
Two of these were case–control studies and one was cross-
sectional. No putative mechanisms for this increase in Lp(a) were
postulated.
One of the studies (cross-sectional design) showed a decreased
level of Lp(a) in subjects with severe pre-eclampsia [32]. Man-
ten et al. [32] postulated that this was  due to more extensive
endothelial damage in severe pre-eclampsia (as compared to mild,
or no pre-eclampsia) and hence higher consumption of Lp(a) as
an acute-phase protein. The authors also acknowledge that the
signiﬁcant difference in GA of their subjects at sampling (208
days for patients with severe pre-eclampsia, compared to 273
days for patients with mild pre-eclampsia) could have affected
outcomes.
The rest of the nine studies (three case–control, one cross-
sectional, one interventional) showed that there was  no difference
in Lp(a) levels in subjects with pre-eclampsia compared to healthy
controls [28,30,31,33,35]. An explanation postulated by Manten
et al., who examined women with a history of pre-eclampsia
(rather than experiencing pre-eclampsia at the time of blood samp-
ling), is that the rise in Lp(a) may  be transient during pregnancy
[31].
What is the role of Lp(a) in pregnancy complicated by IUGR?
Only one study explored the role of Lp(a) in IUGR [31]. This
case–control study showed that there was no difference between
levels of Lp(a) in women with a history of IUGR compared to women
with a history of normal pregnancy. The authors postulated that
this may  be due to a transient rise in Lp(a) during pregnancy, with
return to normal levels post-delivery.
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Table 2
Studies investigating the role of Lp(a) in normal pregnancies and pregnancies affected by conditions other than pre-eclampsia.
Study Design No. pts Population
characteristics
Age of women
(years)
Ethnicity Apo(a) isoform
typing
Method of Lp(a)
measurement
Results Pregnancy
outcomes
Lippi et al. [36] CC 78 57 women  with normal
pregnancies (20 in the
1st trimester, 20 in the
2nd trimester, 17 in the
3rd trimester), 21
non-pregnant women
– – – Nephelometry Increased Lp(a) levels
in subjects in 2nd/3rd
trimesters vs 1st
trimester/non-
pregnant
controls
–
Amundsen et al. [38] CC/L 171 149 healthy women
with normal
pregnancies, 22
pregnant women  with
FH (evaluated at 17–20
weeks, 24, 30, 36
weeks and 3–6 months
PP) (21/22 of women
with FH had
statin-therapy prior to
pregnancy)
Subjects 31.4 ± 4.2,
controls 29.8 ± 3.4
U No Immunoturbidimetry No change in Lp(a)
levels in FH women
during course of
pregnancy
No comparison
between Lp(a) levels in
FH and healthy
controls
No difference in
pregnancy
outcome between
FH and control
groups
Glueck  et al. [40] CC 544 92 women  with a
history of 1 or more
pregnancies and 1
miscarriage, 72 women
with a history of RPL,
380 women  with a
history of 1 or more
pregnancies and 0
miscarriages
U  93% C No U No difference in levels
of Lp(a) between
subjects with history of
miscarriage vs RPL vs
healthy controls
N/A
Krause  et al. [39] CC 266 133 age-matched
healthy controls, 133
women  with
unexplained RPL
Subjects 29
(17–40), controls
28.5 (18–40) (age
at ﬁrst miscarriage)
C Yes (sub-group
analysis)
Apo(a)
isoform-independent
ELISA
Increased levels of
Lp(a) in subjects with
unexplained recurrent
miscarriage vs healthy
controls (p < 0.000)
Increased levels of
small apo(a) isoforms
in subjects with
unexplained recurrent
miscarriage vs healthy
controls (p = 0.002)
Pregnancy
outcome different
between groups
based on study def-
inition/inclusion
criteria (RPL vs
controls)
Manten  et al. [37] L 19 19 healthy women
with normal
pregnancies (assessed
every 4 weeks from 9
to 14 weeks GA, during
labor and at 2–4 weeks
and 3–5 months after
delivery)
30.5 ± 4.4 C Yes Apo(a)
isoform-independent
ELISA
Levels of Lp(a)
increased until 35
weeks of pregnancy,
decreased slightly until
delivery and then fell
to  values below
ﬁrst-trimester levels
No difference in
distribution of apo(a)
isoforms between
subjects vs other
control populations
Mean GA = 278
days
Mean birth-
weight = 3435 g
[Longitudinal
study, therefore no
comparison group]
Lp(a), lipoprotein (a); CC, case–control; CS, cross-sectional; L, longitudinal; FH, familial hypercholesterolemia; PP, post-partum; RPL, recurrent pregnancy loss; Apo(a), apolipoprotein (a); ELISA, enzyme-linked immunoassay; GA,
gestational age; –, information not available; C, Caucasian; U, unknown; N/A, non-applicable (where no difference in Lp(a) levels were recorded between subject and control groups).
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hat is the role of Lp(a) in pregnancy complicated by RPL?
Two studies evaluated levels of Lp(a) in women with a his-
ory of RPL. Both were of case–control design. One (Glueck et al.)
howed no difference in Lp(a) levels in women with a history of one
iscarriage, compared to those with RPL or healthy controls [40].
he other study (Krause et al.) showed increased levels of Lp(a) in
omen with a history of RPL [39]. The authors postulated that this
ould be due to the association of Lp(a) with a hypoﬁbrinolytic state
 promoting thrombosis and hence miscarriage.
hat is the role of Lp(a) in pregnancy complicated by other
onditions?
One study investigated levels of Lp(a) in pregnant women  with
H (Amundsen et al.) [38]. All the women (except one) with FH
n this study had been treated with both dietary modiﬁcation and
tatins prior to pregnancy. Upon planning of pregnancy, statins
ere stopped in all women (except one, who continued to take
tatins into the ﬁrst month of pregnancy). The study design was
oth longitudinal and case–control and showed no change in Lp(a)
evels in pregnant women with FH during the course of pregnancy.
o speciﬁc comparison was made between Lp(a) levels in pregnant
omen with FH, compared to healthy pregnant controls.
iscussion
he role of Lp(a) in normal pregnancy
The two studies exclusively pertaining to Lp(a) levels in normal
regnancy found that Lp(a) levels were raised in normal preg-
ancy compared to non-pregnant controls and that Lp(a) levels
ncreased during the course of pregnancy, respectively [36,37].
his has been shown by previous studies, albeit peak Lp(a) con-
entrations being noted at different gestational ages [41–43].  The
echanism for this rise has variously been postulated to be due
o Lp(a) acting as an acute phase protein in response to endothe-
ial cell damage, or due to metabolic demand for substrates for
ncreased hormone synthesis [37,43]. Other theories include Lp(a)
 in its role as a hypoﬁbrinolytic agent – being necessary for normal
lacental development [41]. Previous studies in normal pregnancy
ave found different results, however, with several demonstrat-
ng no change in Lp(a) during the course of pregnancy [44,45].
ne study, performed with both longitudinal and cross-sectional
esigns, had contrasting ﬁndings. When changes in Lp(a) were eval-
ated in pregnancy by longitudinal follow-up, Lp(a) concentrations
ncreased during pregnancy. However, when Lp(a) concentrations
ere evaluated in pregnancy by cross-sectional design, there were
o signiﬁcant changes in median Lp(a) levels among groups of
regnant women of different gestational ages (1st vs 2nd vs 3rd
rimesters) [46].
he role of Lp(a) in pre-eclampsia
The studies evaluating Lp(a) in pre-eclamptic patients showed
ariously an increased, decreased, or equivalent level of Lp(a)
n pre-eclamptic patients compared to healthy pregnant controls
27–35]. These non-uniform ﬁndings have been similarly produced
n previous papers. Some studies suggest that pre-eclampsia is
ssociated with increased Lp(a) [47–51],  while others suggest that
here is no signiﬁcant difference in the levels of Lp(a) between pre-
clampsia and healthy pregnancy [46,52,53].  Increased levels of
p(a) in pre-eclampsia are thought to be due to more widespread
ndothelial cell damage, necessitating increased levels of Lp(a) to
ct as both an acute phase protein and as a vehicle for cholesterol
eposition at the site of dysfunction (the endothelial cell damagef Cardiology 61 (2013) 99–106
being caused by likely abnormal placental implantation). Where no
change in the level of Lp(a) has been noted in pre-eclampsia, this has
been postulated to be due to endothelial cell damage only being a
local (uterine) change in pre-eclampsia, rather than a systemic one
[52].
The role of Lp(a) in other conditions affecting pregnancy
The limited number of studies investigating Lp(a) levels in the
context of IUGR, RPL, and FH have few other papers to support or
refute their ﬁndings. The study exploring Lp(a) levels in IUGR found
no difference in levels between women  with a history of IUGR and
healthy controls [31]. In previous studies, however, increased lev-
els of Lp(a) have been noted in association with IUGR [48,49]. The
mechanism for this has been suggested to be due to the hypoﬁb-
rinolytic (and hence pro-thrombotic) action of Lp(a), resulting in
poor fetal growth. The ﬁndings that RPL may  be linked with higher
Lp(a) levels have been shown previously and have been postulated
to occur through a similar mechanism [49].
The impact of Lp(a) on pregnancy outcomes
In six of the 14 studies, assessing the impact of Lp(a) on
pregnancy outcome was not applicable – as the authors found
no difference in Lp(a) levels between subjects and controls
[28,30,31,33,35]. In two  of the 14 studies, insufﬁcient information
was available [34,36].  In two of the 14 studies, pregnancy out-
comes were potentially assessable but were not formally assessed
[27,29]. In the study by Wang et al., it was  shown that there was
no difference in Lp(a) levels between subjects and controls [33].
However, the principle outcome of the study was to evaluate the
effects of heparin-mediated apheresis – and pregnancy outcomes
in this study (8 healthy neonates, 1 death from late-onset sepsis)
must be viewed in this context. In the study by Manten et al., it
was shown that reduced birthweight was associated with severe
pre-eclampsia, which was in turn associated with reduced levels
of Lp(a) [32]. In the study by Krause et al., pregnancy outcome was
an intrinsic aspect of recruitment to the study (RPL vs healthy con-
trols) and the authors found higher levels of Lp(a) in subjects with
RPL [39]. In the study by Manten et al., pregnancy outcomes were
recorded, but the impact of Lp(a) could not be assessed as the study
was longitudinal, rather than case–control, in design [37]. In sum-
mary, therefore, the articles evaluated in this review do not answer
the question as to the impact of Lp(a) on pregnancy outcome. This
is in part due to a failure to measure outcomes and in part due
to no difference in Lp(a) levels being recorded between subjects
and healthy controls. In those studies where differences in Lp(a)
levels were noted, a greater range of pregnancy outcomes would
have been useful to evaluate. The question, therefore, remains as to
whether, if Lp(a) is deﬁnitively shown to be raised in pre-eclampsia,
whether it is a cause of pre-eclampsia, a consequence, or a simple
bystander.
Unanswered questions
Nearly all of the studies published since May  2003 have focused
on the concentration of Lp(a) in normal pregnancy and pregnan-
cies affected by pre-eclampsia. Few articles attempted to evaluate
a mechanism for raised Lp(a), or – beyond theorizing – investi-
gate the reasons for raised Lp(a). A few of the questions posed have
been raised by some studies – including evaluating potential ther-
apeutic options and evaluating the effects of Lp(a) on the fetus.
Wang et al. pointed to a role for heparin-mediated apheresis to
enable reduction of raised Lp(a) in the context of pre-eclampsia
[33]. Catarino et al. showed that there was  no difference in Lp(a)
levels in fetuses affected by pre-eclampsia (compared to healthy
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ontrols) [30]. Other recent studies – beyond the search parameters
f this review – have begun to explore the impact of high mater-
al Lp(a) and/or high fetal Lp(a) on neonatal outcomes [54,55].
t is important to note that combining this analysis with that of
re-2003 studies would not alter our conclusions.
imitations of articles reviewed
The fact that only 14 articles were identiﬁed as directly per-
aining to the role of Lp(a) in pregnancy since May  2003 shows
hat, despite controversy, little evidence is available to resolve these
ssues. As a result, it is difﬁcult to draw conclusions from the limited
ata available. Although 11 out of 14 of the studies had a sample
ize of over 50 (and of the three that did not, two were interven-
ional or longitudinal), most of the studies were either case–control
r cross-sectional in design, which renders conclusions on causality
r mechanisms difﬁcult to attain.
In addition, a number of the key recommendations of the Man-
en et al. review have not been implemented by the studies [26].
thnicity was  only documented explicitly in 6 of the 14 stud-
es – and mostly involved Caucasian subjects [31–33,37,39,40].
ot documenting ethnicity leads to difﬁculties in interpreting the
esults, as Lp(a) levels vary according to ethnicity [56–58].  Plasma
oncentration of Lp(a) has been shown to be twice as high in
frican-American patients compared to white Americans, with the
istribution in a bell-shaped frequency (African-Americans) – as
pposed to strongly skewed toward low levels, as seen in white
merican populations [59]. Performing the rest of the studies in
aucasian populations leads to difﬁculties in generalizing the data
o the population as a whole.
In only four of the 14 studies was an apo(a)-independent
ethod of assaying Lp(a) used [31,32,37,39].  Various different
ssays are available to measure Lp(a) concentrations [including
nzyme-linked immunosorbent assay (ELISA), nephelometry and
mmunoturbidimetry] but not all methods take into account the
ize of the apo(a) isoform – thus rendering analysis inaccurate [60].
iven that apo(a)-dependent forms of measurement may  cause
ver- or under-estimations of Lp(a) concentrations, the method-
logies of these studies are sub-optimal. In only 3 of the 14 studies
ere attempts made to identify apo(a) isoforms [32,37,39].  Given
he fact that the smaller the apo(a) isoform, the higher the con-
entration of Lp(a), not commenting on whether the nature of the
po(a) isoforms were different between study and control groups
epresents a potential hidden source of bias in the other studies
27–31,33–36,38,40].
onclusion
This review demonstrates that there is still no clear role of Lp(a)
n either normal or complicated pregnancies. The studies analyzed
n this review provide differing accounts, based likely in part due
o differing methodologies, with no consensus trend. Therefore –
s with previous reviews, no conclusion can be reached as to the
eﬁnitive role of Lp(a) in pregnancy. However, multiple studies
ndicate that there may  be a role for Lp(a) in pathological pro-
esses in pregnancy and in pregnancy outcomes. Further studies
re needed of more uniform methodology – preferably involv-
ng larger sample size, ethnically diverse populations, identifying
po(a) isoforms and using apo(a)-independent assays. In addi-
ion, work in the laboratory should focus on identifying possible
echanisms.eferences
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